ArticleMetabolic brain disease2026
Metabolic dysregulation in psychotic mania: longitudinal cardiometabolic changes with exploratory analyses of serum uric acid.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychotic mania, a severe form of bipolar disorder, presents with elevated mood, hyperactivity, and psychotic symptoms. It is frequently accompanied by metabolic dysregulation, increasing the risk of metabolic syndrome and cardiovascular morbidity. This study investigates whether serum uric acid and metabolic parameters can serve as state or trait biomarkers in individuals with psychotic mania. It further examines their relationships with clinical outcomes and psychopathological changes across various phases of the illness. This study employed a prospective study design involving 30 patients with psychotic mania, 30 first-degree relatives, and 30 age- and sex-matched healthy controls. Serum uric acid levels and various metabolic parameters were analyzed concurrently to elucidate their potential interrelationship. Serum uric acid levels showed no significant changes between baseline (mean ± SD: 5.84 ± 1.74 mg/dL) and follow-up (mean ± SD: 5.15 ± 1.63 mg/dL). However, notable increases were observed in triglycerides (from 125.73 ± 69.67 to 169.07 ± 72.46 mg/dL, p = 0.010), systolic blood pressure (from 116.80 ± 7.59 to 119.80 ± 6.99 mm Hg, p < 0.001), and body mass index (BMI) (from 20.90 ± 3.91 to 21.12 ± 3.91 kg/m², p < 0.001). Negative correlations emerged between changes in uric acid and select metabolic indicators, including triglycerides and low-density lipoprotein (LDL). This study demonstrates the necessity for integrated care approaches that address both psychiatric symptoms and metabolic health in patients with psychotic mania, emphasizing the potential of uric acid as a marker of underlying metabolic dysfunction.
Indexed as
Identifiers
41779246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.